Acusphere (Watertown, Massachusetts) said last month that it has entered into a collaboration, license and supply agreement with Nycomed (Roskilde, Denmark) for the European development and marketing rights to Acusphere’s lead product candidate, AI-700, an ultrasound contrast agent currently in Phase III clinical trials for assessing myocardial perfusion in the diagnosis of coronary heart disease.